Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.89 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598757 | 0.98 | ALDH1A1 (0.85) | ALDH1A1KDM4EHTR6L3MBTL1POLB | |
| SCHEMBL25687896 | 0.98 | ALDH1A1 (0.85) | ALDH1A1KDM4EHTR6L3MBTL1POLB | |
| SCHEMBL337149 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EL3MBTL1POLBKMT2A | |
| SCHEMBL337396 | 0.94 | ALDH1A1 (1.00) | ALDH1A1KDM4EL3MBTL1POLBKMT2A | |
| SCHEMBL7383705 | 0.92 | ALDH1A1 (0.75) | ALDH1A1KDM4EHTR6L3MBTL1POLB | |
| SCHEMBL11329761 | 0.90 | ALDH1A1 (0.72) | ALDH1A1KDM4EHTR6L3MBTL1POLB | |
| SCHEMBL2301305 | 0.86 | ALDH1A1 (0.71) | ALDH1A1KDM4EHTR6L3MBTL1POLB | |
| SCHEMBL337373 | 0.86 | ALDH1A1 (0.85) | ALDH1A1KDM4EL3MBTL1POLBKMT2A | |
| SCHEMBL24221675 | 0.82 | KDM4E (0.71) | ALDH1A1KDM4EPOLB | |
| SCHEMBL25669872 | 0.80 | ALDH1A1 (0.64) | ALDH1A1KDM4EL3MBTL1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058315-A1 | 2-Oxo-ethanesulfonamide derivates | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | claimed |
| EP-1562574-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041264-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| JP-3258720-A | — | — | None | — | — | JP | disclosed |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2024-11-05 | — | — | US | disclosed |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | UNIV YALE (US) | 2022-03-03 | — | — | US | disclosed |
| US-11142503-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-20200392086-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | UNIV YALE (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3434669-B1 | INTERMEDIATE COMPOUNDS UTILIZABLE IN SYNTHESIS OF (-) HUPERZINE AND PROCESS FOR OBTAIN ONE OF THESE INTERMEDIATE COMPOUNDS | UNIV YALE (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | YALE UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060058315-A1 | 2-Oxo-ethanesulfonamide derivates | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1562574-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041264-A1 | 2-OXO-ETHANESULFONAMIDE DERIVATES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| EP-0703908-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5461047-A | Analgesics and treats prostaglandin-E2 mediated diseases in animals | G. D. SEARLE & CO. (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1994029286-A1 | ANALGESIC DIBENZOXAZEPINES AND DIBENZOTHIAZEPINES | G.D. SEARLE & CO. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5354747-A | Analgesics | G. D. SEARLE & CO. (US) | 1994-10-11 | — | — | US | disclosed |
| JP-H03258720-A | CEREBRAL METABOLISM ACTIVATING AND PROTECTING AGENT AND CEREBRAL FUNCTION IMPROVING AGENT | TAIHO YAKUHIN KOGYO KK | 1991-11-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781179-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | ALDH1A1 341/4885KDM4E 1782/4885HTR6 131/4885 |
| US-11142503-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | ALDH1A1 341/4885KDM4E 1782/4885HTR6 131/4885 |
| US-20200392086-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | CHRNA5, HTR2A, HTT | ALDH1A1 316/4885KDM4E 1487/4885HTR6 143/4885 |
| US-20060058315-A1 | 2-Oxo-ethanesulfonamide derivates | HSD11B1, HSD3B1, HSD11B2 | ALDH1A1 65/4885KDM4E 1918/4885HTR6 2960/4885 |
| US-12134602-B2 | (−)-huperzine A processes and related compositions and methods of treatment | CHRNA5, HTR2A, GRIK5 | ALDH1A1 341/4885KDM4E 1782/4885HTR6 131/4885 |
| US-20220064123-A1 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | CHRNA5, HTR2A, HTT | ALDH1A1 316/4885KDM4E 1487/4885HTR6 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.